Stock Quote

VistaGen Therapeutics and EverInsight Therapeutics Enter Strategic Collaboration to Develop and Commercialize PH94B for Anxiety Disorders in Greater China, South Korea and Southeast Asia

The collaboration is intended to support Phase 3 development and commercialization of PH94B in key Asian markets. The agreement includes a $5 million upfront payment and development and commercial milestones up to $172 million.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.